In chronic myeloid leukemia (CML), the cancer’s development and progression and erythropoiesis can be regulated by CT10 regulation of kinase-like (CRKL) (not CRKII) and miR-429 via the activation of the Raf/MEK/ERK pathway [50]. Here, MAGEC2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.